Study shows miR-1910-5p predicts poorer 5-year prognosis in glioma patients, highlighting GPX8's role in tumor growth.
Objectives The suboptimal prognosis of glioma patients after treatment underscores the critical significance of elucidating the intricate molecular mechanisms underlying glioma progression. This study endeavors to excavate reliable biomarkers in order to advance the treatment of gliomas. Methods A total of 133 glioma patients were enrolled in this study, with glioma tissues and adjacent normal tissues collected during surgery. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to detect miR-1910-5p expression, and Kaplan-Meier analysis was conducted to assess its predictive value for patient survival within 5 years post- surgery. Bioinformatic approaches were utilized to identify potential targets of miR-1910-5p, which were subsequently validated using a luciferase reporter gene system. Ultimately, the influence of miR-1910-5p/GPX8 on cell proliferation and metastasis was analyzed by CCK8 and Transwell assays. Results miR-1910-5p expression was markedly down-regulated in glioma tissues and cells. Notably, a lower miR-1910-5p level was associated with a poorer 5-year prognosis for glioma patients. GPX8, on the other hand, was significantly up-regulated in gliomas and exhibited a negative correlation with miR-1910-5p expression, suggesting a unidirectional negative regulation of GPX8 by miR-1910-5p. Further analysis revealed that miR-1910-5p overexpression suppressed glioma cell proliferation and metastasis, with these effects being significantly reversed by GPX8 overexpression. Conclusions miR-1910-5p has the potential to serve as a prognostic marker of glioma and may exert its inhibitory effects on glioma cellular behaviors by targeting GPX8.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: